Silo Pharma Inc 2026年季度报告

FORM 10-Q (Mark One) ☒QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-41512 SILO PHARMA, INC.(Exact name of registrant as specified in its charter) Nevada27-3046338(State or other jurisdiction of(IRS Employer Registrant’s telephone number, including area code:(718) 400-9031 Securities registered pursuant to Section 12(b) of the Exchange Act: Name of exchange on which registered The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistration was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ Number of shares of common stock, par value $0.0001 per share, outstanding as of May 13, 2026 was: 16,266,593. SILO PHARMA, INC. AND SUBSIDIARYFORM 10-QMARCH 31, 2026 TABLE OF CONTENTS PagePART I – FINANCIAL INFORMATIONItem 1.Financial Statements1Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 20251Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2026and 2025 (Unaudited)2Consolidated Statements of Changes in Stockholders’ Equity for the Three Months Ended March 31, 2026 and2025 (Unaudited)3Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025 (Unaudited)4Condensed Notes to Consolidated Financial Statements (Unaudited)5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations25Item 3.Quantitative and Qualitative Disclosures About Market Risk34Item 4.Controls and Procedures34 Item 1.Legal Proceedings35Item 1A.Risk Factors35Item 2.Unregistered Sales of Equity Securities and Use of Proceeds35Item 3.Defaults Upon Senior Securities35Item 4.Mine Safety Disclosures35Item 5.Other Information35Item 6.Exhibits36 CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. Allstatements, other than statements of historical facts, contained in this report, including statements regarding our strategy, futureoperations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expectedmarket growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as“may,” “could,” “will,” “would,” “should,” “expect,” “plan,”, “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,”“contemplate,” “project,” “continue,” “potential,” “ongoing” or the negative of these terms or other comparable terminology. Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed throughout this QuarterlyReport on Form 10-Q. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially fromestimates or projections contained in the forward-looking statements include, but are not limited to: ●our ability to obtain additional funds for our operations;●our financial performance;●risks relating to the timing and costs of clinical trials and the timing and costs of other expenses;●risks related to market acceptance of products;●intellectual property risks;●the impact of government regulation and developments relating to our competitors or our industry;●our competitive position;●our industry environment;●our anticipated financial and operating results, including anticipated sources of revenues;●assumptions regarding the size of the available market, benefits of our products,